Clinical Toxicity of Interferon in Cancer Patients | 90152
International Research Journals

Clinical Toxicity of Interferon in Cancer Patients


Anubha Bajaj*

Interferon (IFN) has been designated as a typical biological response modifier (BRM). Like corticosteroids, they cause a variety of physiological changes [1]. Therefore, IFNs act through a mechanism different from conventional cell proliferation inhibitors, and their therapeutically optimal doses in cancer treatment may not necessarily correspond to the maximum tolerated dose. Optimal treatment for cancer includes different treatments and combinations of different medicines. Experimental studies have shown that IFN can be effectively combined with radiation and chemotherapy. In addition, IFN enhances mutual effects and the effects of other biopharmaceuticals. [2] Such a new combination approach provides an opportunity to overcome the resistance of malignant cells. Preliminary evidence from Phase I and II studies shows that qualitatively similar clinical toxicity occurs in IFNα, IFNβ and IFNγ. Untreated to further define the clinical spectrum of adverse events associated with different types, doses, and schedules of IFN immunotherapy and combination therapy, and to select a series of routine tests to monitor IFN toxicity. Four phase II trials from a study of 43 lung cancer patients [3].

Share this article